Spin out success
13 May 2010 by Evoluted New Media
Spin out company MGB BioPharma has been created by the University of Strathclyde to commercialise antibacterial technology and has received almost £2 million in funding.
Spin out company MGB BioPharma has been created by the University of Strathclyde to commercialise antibacterial technology and has received almost £2 million in funding.
|
Strathclyde researchers develop antibacterial technology which could be used to fight MRSA |
The antibacterial technology has demonstrated very significant in vitro and in vivo activity against Gram positive bacteria including MRSA and some Gram negative bacterial. It also involves a new class of DNA minor groove binders (MGBs).
“The introduction of a new class of antibacterial is all too rare an event in medical science,” said Miroslav Ravic, chief executive officer of MGB BioPharma, “We are particularly proud to be working with the DNA Minor Groove Technology from the University of Strathclyde. I believe the last Scottish association with the discovery of a new antibacterial class was none other than that of Alexander Flemming’s discovery of penicillin 82 years ago.”
The funding comes from an angel syndicate led by Archangel Informal Investments in association with TRI Cap Ltd, Barwell plc and the Scottish Co-investment Fund.
